COMPANY PROFILE
"Bringing Therapies to Life"
Strategic Quote
"We have the capacity, scalability, and reproducibility to accelerate your therapy. Experience the spaces where your therapies are brought to life. Explore our cell therapy cGMP facilities and manufacturing capabilities."
Summary
Genezen is a technical and quality-focused CDMO dedicated to advancing gene and cell therapies by providing cutting-edge viral vector services and manufacturing solutions. When you’re ready to start or shift your CDMO journey, our team offers the expertise, technology, and flexibility to help bring your viral vector-based therapy to patients.
Our facility in the fast-growing biotech hub of Indianapolis provides you with the essential capacity and latest technologies dedicated to the aseptic manufacture of a wide range of viral vector manufacturing modalities.
We offer:
- 10+ years of CGT experience
- 60,000 ft2 cGMP compliant facility in Fishers, Indiana
- 86,000 ft2 licensed viral vector manufacturing in Lexington, Massachusetts
Our Team
The Genezen team boasts deep gene and cell therapy development and manufacturing expertise. We are committed to scientific excellence and act with urgency for you and your patients. We operate with resilience and grit, execute with excellence and integrity at all times, and are solutions-driven for our partners.
Steve Favaloro, Chairman and Chief Executive Officer:
Steve Favaloro is an experienced biotech executive, board member, and investor. He is currently Chairman and CEO of Genezen, a leading gene and cell therapy CDMO. He is an executive advisor at Ampersand Capital Partners, a leading healthcare investor, and also serves on the boards of Vernal Bio, Biologos, and Orthobond. Prior to Genezen, Steve was CFO at Arbor Biotechnologies, a next-generation gene editing therapeutic company.
Susan D’Costa, Chief Technical & Commercial Officer:
Susan D’Costa is a molecular virologist spanning 25 years of experience in virology. Over the past ten years she has been actively involved in viral vector analytics, process development, manufacturing, and building successful teams. She is currently the Chief Technical and Commercial Officer at Genezen, a leading gene and cell therapy CDMO. Prior to Genezen, Susan was CTO at Alcyone Therapeutics, a biotechnology company pioneering next-generation CNS precision gene-based therapeutics for complex neurological conditions.
Why Genezen?
At Genezen, we bring therapies to life. We are a CDMO dedicated to advancing gene and cell therapies by providing science-driven development and manufacturing solutions.
